Skip to main content

Table 2 Between and within groups differences on the pulmonary function test, 6-min walking test (6MWT), and laboratory data at the baseline, at 4 weeks, and after 12 weeks (N = 44)

From: Effect of high-flow nasal therapy during early pulmonary rehabilitation in patients with severe AECOPD: a randomized controlled study

 Non-HFNT PRHFNT PRBetween-group test
Baseline (n = 22)4 weeks (n = 22)12 weeks (n = 22)Baseline (n = 22)4 weeks (n = 22)12 week (n = 22)4 weeks12 weeks
p value
Pulmonary function test
 FVC, L2.29 ± 0.762.38 ± 0.73**a2.40 ± 0.74**a2.26 ± 0.682.38 ± 0.692.42 ± 0.690.9900.932
 FEV1, L0.83 ± 0.240.84 ± 0.2337.5 ± 39.60.86 ± 0.260.88 ± 0.260.92 ± 0.26**a,b0.5500.324
 FEV1/FVC, %39.6 ± 12.839.6 ± 12.539.6 ± 12.540.2 ± 11.040.3 ± 11.240.4 ± 11.60.8400.833
 Delta IC, L−0.22 ± 0.18−0.18 ± 0.16−0.16 ± 0.15*a−0.18 ± 0.17−0.13 ± 0.12*a−0.09 ± 0.13**a0.1460.099
6MWT
 6MWD, m128.5 ± 85.6191.4 ± 89.3245.5 ± 103.1**a,b178.9 ± 81.6260.1 ± 87.7**a304.6 ± 84.4**a,b0.014c0.044c
 SpO2, % pre 6MWT94.4 ± 3.495.0 ± 3.195.5 ± 2.6*a93.8 ± 2.595.1 ± 2.4*a95.6 ± 2.1**a0.9570.802
 SpO2, % post 6MWT87.4 ± 4.288.9 ± 4.9*a90.5 ± 2.8**a,b88.9 ± 4.490.7 ± 3.1**a91.8 ± 2.4**a0.1360.103
 HR, pre 6MWT98.4 ± 10.792.1 ± 11.3**a91.7 ± 10.8**a96.5 ± 11.592.6 ± 10.5**a91.3 ± 10.4**a0.8800.899
 HR, post 6MWT125.6 ± 8.1124.4 ± 7.8125.1 ± 7.4125.6 ± 14.0122.7 ± 6.4122.0 ± 6.60.4260.141
Laboratory data
 WBCs, 103/μl14.80 ± 5.228.73 ± 2.01**a7.92 ± 1.56**a14.71 ± 4.448.18 ± 2.65**a7.06 ± 1.51**a0.4390.072
 CRP, mg/dl8.41 ± 6.771.73 ± 1.73**a0.30 ± 0.39**a5.11 ± 5.601.07 ± 1.57**a0.07 ± 0.12**a0.1920.020c
 pH7.36 ± 0.087.40 ± 0.04**a7.42 ± 0.05**a7.36 ± 0.087.41 ± 0.05*a7.42 ± 0.04**a0.4790.949
 PaCO2, mmHg51.5 ± 24.145.1 ± 15.5*a45.1 ± 13.5*a52.6 ± 20.340.1 ± 5.5*a46.0 ± 17.0**a0.7520.755
 PaO2, mmHg63.2 ± 15.382.9 ± 21.0**a81.9 ± 18.0**a66.1 ± 14.782.7 ± 16.8**a83.1 ± 17.3**a0.9760.825
 HCO324.88 ± 4.2425.04 ± 5.82*a27.35 ± 4.51*a,b26.26 ± 5.9827.15 ± 4.0428.75 ± 4.15*a0.1690.290
  1. Values are the mean ± SD; Delta inspiratory capacity (IC), post-6MWT IC - pre-6MWT IC
  2. a Baseline vs. 4 weeks and 12 weeks; b 4 weeks vs. 12 weeks; * p < 0.05, ** p < 0.01; c delta, 12 weeks - baseline and 4 weeks - baseline
  3. Abbreviations: FEV1 forced expiratory volume in the first second; FVC forced vital capacity; 6MWD, 6-min walking distance; SpO2 oxyhemoglobin saturation by pulse oximetry; HR heart rate; IC inspiratory capacity; WBCs white blood cells; CRP C-reactive protein; PaCO2 partial pressure of carbon dioxide; PaO2 partial pressure of oxygen; HCO3 hydrogen carbonate bicarbonate ion